SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus remedies receives US patent protection for Potentox

26 Jul 2012 Evaluate

Venus Remedies, a research based global pharmaceutical company, has secured its third US patent for its another novel antibiotic product -- POTENTOX. Granted by the United States Patent and Trademark Office, the patent protects the composition of POTENTOX and the method of treatment.

The patent provides an exclusivity period for POTENTOX until May, 2027. In addition to this new patent grant, POTENTOX is protected by a number of other patents from across the Globe including India, Australia, New Zealand, South Korea, South Africa and Ukraine. Potentox is an antibiotic adjuvant entity (AAE); a new drug product effective in case of Hospital Acquired Pneumoniae and Febrile Neutropenia infections, Quinolones or Aminoglycoside resistant cases.

Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness and greater risk of death. Getting a patent grant for POTENTOX from US at such point in time can prove to be all the more significant for society at large as the drug works synergistically on Multi-drug resistant bacteria that not only halts the development of bacterial resistance but also its spread.

The company has already been marketing POTENTOX successfully in India and few of the emerging markets around the globe. The product is growing with a CAGR of 50% since past 3 years and now Venus is planning to have a pre IND meeting with US FDA for fast track approval of this product. The company is also open for the strategic tie-ups with the international pharma companies.

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×